TrialInvestigational new drugs2013

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.

Robert Dreicer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.